The DOI matches its Crossref record.
Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature
Abstract
Mebendazole and albendazole are the drugs of choice for the treatment of alveolar echinococcosis. In this open-labelled observational study we present and evaluate the outcome of long-term treatment with these drugs and present results of different treatment regimens. Thirty-five patients were started on either mebendazole or albendazole at the beginning of 1992 and followed for an average of 39 months (range 12-79 months). Treatment was classed as successful if the disease had not progressed for >1 year and if there were no side-effects necessitating a change of treatment. Lack of progression was evaluated mainly using ultrasound and computed tomography and was further substantiated by laboratory tests and clinical findings. The overall success rate was 97%. An initial regimen for cases of alveolar echinococcosis was recurrence-free in 71% of those treated with mebendazole and in 78% of those treated with albendazole. Four out of five cases with progressive disease stabilized after the therapeutic regimen was changed. Seven patients received a continuous regimen with albendazole. These patients were observed over an average of 28 months (range 13-50 months) without signs of progression or significant side-effects. This open-labelled prospective study demonstrates the high therapeutic efficacy of both mebendazole and albendazole with similar response rates in the treatment of alveolar echinococcosis. Albendazole reduced costs by >40% and is easier for patients to take, further arguing in favour of its preferred use. Albendazole in alveolar echinococcosis is only licensed for intermittent application. None the less, continuous treatment is safe and well tolerated and showed promising results when applied to patients in whom other treatment regimens had failed. It should thus be strongly considered in inoperable cases or progressive disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans
Brunetti, E., Kern, P., & Vuitton, D. A. (2010) · Acta Tropica · doi:10.1016/j.actatropica.2009.11.001 · Cited by 2,183
Eckert, J., & Deplazes, P. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.1.107-135.2004 · Cited by 1,945
Rodent-borne diseases and their risks for public health
Meerburg, B. G., Singleton, G. R., & Kijlstra, A. (2009) · Critical Reviews in Microbiology · doi:10.1080/10408410902989837 · Cited by 1,003
(2017) · Advances in Parasitology · doi:10.1016/bs.apar.2016.09.006 · Cited by 502
European Echinococcosis Registry: Human Alveolar Echinococcosis, Europe, 1982–2000
Kern, P., Bardonnet, K., Renner, E., Auer, H., Pawlowski, Z., Ammann, R. W., Vuitton, D. A., Kern, P., & the European Echinococcosis Registry (2003) · Emerging Infectious Diseases · doi:10.3201/eid0903.020341 · Cited by 394
Hepatic echinococcosis: Clinical and therapeutic aspects
Nunnari, G. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i13.1448 · Cited by 381
Treatment of echinococcosis: albendazole and mebendazole – what else?
Hemphill, A., Stadelmann, B., Rufener, R., Spiliotis, M., Boubaker, G., Müller, J., Müller, N., Gorgas, D., & Gottstein, B. (2014) · Parasite · doi:10.1051/parasite/2014073 · Cited by 173
Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2159 · Cited by 152
Metadata
- Authors
- Reuter, S.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-09-01
- Volume
- 46
- Issue
- 3
- Pages
- 451-456
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2122008242
- Cited by
- 171
- References
- 0
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.